Understanding the Key Differences Between EBO2 and EBO3

EBO3 is a clinic-branded wellness protocol. These references describe ozone's regulatory context and the state of the published evidence; they do not establish EBO3 as a treatment for any disease, and ozone therapy is not FDA-approved. Published EBOO/ozone literature is heterogeneous, largely preliminary or uncontrolled, and mostly of low or very-low certainty.

• 21 CFR § 801.415 — Federal regulation on ozone (labeling context)

  eCFR (U.S. Electronic Code of Federal Regulations)

  Federal labeling regulation for medical devices generating ozone. Regulatory context only; does not indicate FDA approval of ozone as a therapy.

• Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful

  Mediators of Inflammation (PMID 16156950)

  Narrative review discussing extracorporeal blood oxygenation with ozone (EBOO) and related ozone modalities. Evidence at the time was preliminary and largely uncontrolled — insufficient to validate EBOO for any disease indication.

• Umbrella review of ozone therapy across clinical indications

  Medical Sciences (DOI 10.3390/medsci14020289)

  Umbrella review of systematic reviews of ozone therapy across multiple indications. Findings are heterogeneous with most conclusions rated low or very-low certainty; overall evidence remains insufficient to establish general clinical efficacy.

• Smith NL et al. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility

  Medical Gas Research (PMID 29152215)

  Peer-reviewed overview of ozone therapy noting that the current clinical evidence base is heterogeneous and further rigorous study is needed.

References describe general evidence, safety, or regulatory context. They do not establish an individual benefit for any specific person, and they do not validate EBO2's proprietary clinic protocols.